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Abstract
Objectives:
The aim of this prospective, open-label study was to evaluate the efficacy and tolerability of tapentadol (TP)
in the management of cancer pain.
Methods:
A 4 weeks’ prospective study was carried out in 50 opioid-naive cancer patients with moderate–severe pain.
Each patient initially received twice-daily doses of slow-release TP 50mg. Doses were then managed to
maintain adequate relief or dose-limiting toxicity, on the basis of the clinical response. The following
parameters were recorded at weekly intervals for 4 weeks: pain and opioid-related adverse effects,
quality of life measured with the Spitzer score, TP escalation index percent (TPEI%) and TP escalation
index in mg (TPEImg), calculated at the end of the study, pain mechanisms, and PainDETECT at baseline.
Results:
Of 50 patients, 39 completed the entire study and 11 discontinued the treatment for different reasons. Pain
intensity significantly decreased from baseline to all the week intervals (p50.0005), and adverse effects did
not changed significan ly, while quality of life improved. TP escalation indexes were low and no relationship
was found with age, gender, and pain mechanisms.
Conclusion:
Tapentalol started in doses of 100mg/day was well-tolerated and effective in opioid-naive patients with
cancer pain, regardless of the pain mechanism. It can be considered as a flexible drug to be used in patients
with moderate–severe pain.
Limitations:
This was an open-label study for exploratory purposes. Data should be confirmed in controlled studies with a
larger number of patients.
Introduction
Cancer pain management is based on a sequential approach of drugs, as sug-
gested by the WHO, through steps corresponding to drugs with different poten-
cies. Application of the WHO three-step analgesic ladder has been reported to
provide satisfactory pain relief in up to 90% of patients with cancer pain1. This
approach has had an impact of paramount importance in terms of clinical out-
come and educational perspective, although evidence is lacking, particularly
with regard to possible alternatives, because of the paucity of controlled studies
in this field. More recently, studies have examined the role of opioid analgesics
and confirmed that more data are necessary2. It is anticipated that new drugs will
be evaluated in the near future.
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Tapentadol (TP) is a novel, centrally acting analgesic
agent with two mechanisms of action: as a mu opioid
receptor agonist and by norepinephrine reuptake
inhibition. TP has been developed for the management
of moderate–severe chronic pain. The moderate affinity
at the mu receptor and the opioid-sparing effect of inhibi-
tion of norepinephrine reuptake suggest that TP should
produce fewer opioid-related adverse effects than typical
mu agonists3. TP has been shown to be effective in a vari-
ety of pain models. In these models the development of
tolerance was considerably delayed with TP compared to
morphine4–6. In humans, efficacy and safety of TP have
been demonstrated in comparative studies with placebo
and oxycodone in several non-malignant conditions7–10,
but have never been assessed in patients with cancer pain.
This class of patients, in contrast to non-cancer patients
with pain, may require high doses of opioids, owing to
disease-related factors, pain characteristics, as well as pro-
longed use. Thus, it is of paramount importance to gather
information about the use of this new drug with its unusual
pharmacologic characteristics in this context.
TP is available as controlled-release tablets to be
administered twice daily. The aim of this prospective,
open-label study was to evaluate the efficacy and tolera-
bility of TP in the management of cancer pain. The sec-
ondary outcome was to evaluate the tendency to increase
the dose in the medium-term.
Patients and methods
A prospective study was carried out on a sample of 50
consecutive advanced cancer patients with moderate–
severe pain. Informed consent and institutional approval
from the University of Palermo were obtained. Inclusion
criteria were: moderate–severe cancer pain (more than 4
on a numerical scale from 0 to 10, see below), unresponsive
to step one analgesic ladder drugs (non-opioid drugs), or
occasional use of opioids for moderate pain, and a
Karnofsky status of 50 or more. Exclusion criteria were:
poor renal or hepatic function, history of drug abuse, cog-
nitive failure, brain metastases or brain damage, and short
expected survival.
Each patient initially received twice-daily doses of
slow-release TP 50mg, and oral morphine as rescue med-
ication (5mg initially). Doses were thenmanaged to main-
tain adequate relief or dose-limiting toxicity, on the basis
of the clinical response. If patients were receiving non-
opioid analgesics, these were continued, if tolerated by
patients. Adjuvant-symptomatic drugs were used accord-
ing to clinical need and departmental policy. Patients were
visited or contacted at least once weekly to change ther-
apy, according to the clinical status. The following param-
eters were recorded before starting the study (T0), 1 week
after (W1) and at weekly interval for 4 weeks (W2,W3,
and W4):
 Pain intensity monitored using a numerical scale from
0 to 10.
 Symptoms associated with opioid therapy or which are
commonly present in advanced cancer patients, such
as nausea and vomiting, drowsiness, confusion, and
dry-mouth were rated using a scale from 0 to 3 (not
at all, slight, a lot, severe). Constipation was assessed as
follows: 0¼ stool in the previous 24 hours; 1¼ 2 days
before; 2¼ 3 days before; 3¼ 4 or more days before, or
need for clyster.
 Quality of life measured with the Spitzer score (5 items
including activity, daily living, health, support, out-
look, from 0 to 2, for a maximum score 10), which is
considered a well-validated system11.
 The TP escalation index percent (TPEI%) was calcu-
lated at W4. This score expresses the mean percentage
increase of opioid dosage from opioid starting dose
(TPSD), according the following formula: [(TPMD–
TPSD)/TPSD]/days 100, where TPMD is the maxi-
mal dose of TP. The TP escalation index in mg
(TPEImg) was calculated as the mean increase of TP
dosage in mg using the following formula: (TPMD–
TPSD)/days12.
 The pain mechanisms were considered on the basis of
clinical history, anatomical site of primary tumor and
distant metastases, physical examination, investiga-
tions such as CT-scan, MNR and so on, when neces-
sary. The PainDETECT questionnaire was used to
determine the prevalence of neuropathic pain
components13.
Statistical analysis
Frequency analysis was performed with the chi-square test
and Fisher’s exact test, as needed. The paired Wilcoxon
signed-rank test was used to compare pain intensity scores
and symptom intensity scores in the four weekly periods.
The paired samples Student t-test was used to compare
opioid mean dose in the four weekly periods. The one-
way analysis of variance (ANOVA) and the Kruskal–
Wallis statistic test were used to evaluate the differences
in TPEI% and TPEImg for parametric and nonparametric
variables, respectively. All p-values were two-sided and p-
values less than 0.05 were considered to indicate statistical
significance. Data were analyzed by Epi Info software, ver-
sion 3.2.2, (Centers for Disease Control and Prevention,
Atlanta, Georgia, USA) and Systat Software 8.0 version
(SPSS, Inc.).
Results
Of 50 patients recruited for the study, 30 were female, and
the mean age was 66.3 years (SD 13.9). The mean
Current Medical Research & Opinion Volume 28, Number 11 November 2012
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Karnofsky status was 67 (SD 11.2). Primary tumors were in
a rank order: breast (n¼ 13), urogenital (n¼ 10), gastro-
intestinal (n¼ 9), lung (n¼ 7), pancreas (n¼ 5), others
(n¼ 6). Eleven patients did not conclude the study or dis-
continued TP for different reasons: three patients died
during the study period, three patients had adverse effects
requiring to a switch to other opioid analgesics, four
patients manifested poor compliance to the treatment,
and one patient was lost to follow-up.
Data regarding pain and symptoms at the different time
intervals are presented in Table 1. Pain intensity signifi-
cantly decreased from baseline to all the week intervals
(p50.0005).
Some symptoms varied in intensity during the study
period. Drowsiness significantly increased at W1
(p¼ 0.034), and decreased at W4 (p¼ 0.030). Dry
mouth increased from W1 to W3 (p¼ 0.018), and
decreased from W1 to W4 (p¼ 0.026). No significant
changes were observed in intensity of confusion, nausea,
and constipation. The Spitzer score significantly increased
at W1 (p¼ 0.014), W2 (p¼ 0.028), W3 (p¼ 0.006), and
W4 (p¼ 0.001).
From clinical evaluation, ten patients had somatic pain,
six patients had visceral pain, and one patient had neuro-
pathic pain. Mixed syndromes were more frequent: 19
patients had somatic-neuropathic pain, 11 patients had
somatic and visceral pain, two patients had visceral-neu-
ropathic pain, and one patient had somatic-visceral and
neuropathic pain. PainDETECT mean value was 5.4 (SD
6). The values were negative, positive, and uncertain in
23, 19, and eight patients, respectively. No difference in
the use of adjuvants was observed during the study period
(Table 2).
TPEI% and TPEImg were 1.78 (SD 2.5) and 2.26
(SD 3.3), respectively. No relationship between TPEI
indexes and primary tumor (TPEI%, p¼ 0.829, TPEImg,
p¼ 0.868), pain mechanism (TPEI%, p¼ 0.488, TPEImg
p¼ 0.353), painDETECT (TPEI%, p¼ 0.516, TPEI%,
p¼ 0.777), age (TPEI%, p¼ 0.079, TPEImg p¼ 0.183), or
gender were found (TPEI%, p¼ 0.105, TPEImg p¼ 0.217).
Discussion
The present study evaluated TP with starting doses of
100mg/day in opioid-naive patients with moderate–
severe cancer pain. Pain intensity significantly decreased
to acceptable levels during the study period. The dose of
TP, given according to the patients’ clinical response,
slowly increased over 4 weeks, with low escalation indexes.
TPEI calculated in this study was even lower than that
observed in previous studies with a similar design in
Table 2. Doses of tapentadol (mean, SD) and frequency of use (%) of adjuvants at time intervals T0¼ baseline, W1¼ 1st week, W2¼ 2nd week, W3¼ 3rd
week, W$¼ 4th week.
T0 W1 W2 W3 W4
Tapentadol dose, mg, mean (SD) 146 (86) 173 (96) 180 (107) 190 (114)
Antiemetics n (%) 14 (28) 18 (36) 18 (40) 19 (47) 13 (34)
Laxatives n (%) 12 (24) 15 (30) 14 (31) 13 (32) 11 (29)
Corticosteroids n (%) 11 (22) 12 (24) 10 (22) 10 (25) 8 (21)
Antidepressants n (%) 5 (10) 5 (10) 4 (9) 4 (10) 3 (8)
Anticonvulsants n (%) 7 (14) 5 (10) 7 (15) 7 (17) 8 (21)
Neuroleptics n (%) 2 (4) 3 (6) 3 (6) 2 (5) 1 (2)
Benzodiazepines n (%) 7 (14) 5 (10) 3 (6) 4 (10) 4 (10)
NSAIDs – paracetamol n (%) 7 (14) 2 (4) 3 (6) 2 (5) 4 (10)
Table 1. Pain, symptom intensity and Spitzer score at time intervals: T0¼ baseline, W1¼ 1st week, W2¼ 2nd week, W3¼ 3rd week, W4¼ 4th week.
T0 W1 W2 W3 W4
No. patients 50 49 45 40 38
Pain 5.88 (1.5) 2.79 (1.8) 2.33 (1.4) 2.05 (1.5) 1.71 (1.1)
Nausea 0.20 (0.4) 0.16 (0.4) 0.11 (0.3) 0.15 (0.4) 0.13 (0.3)
Drowsiness 0.14 (0.3) 0.26 (0.5) 0.24 (0.5) 0.12 (0.3) 0.08 (0.2)
Confusion 0.04 (0.2) 0.08 (0.2) 0 0.10 (0.3) 0
Dry mouth 0.60 (0.7) 0.49 (0.6) 0.71 (0.7) 0.70 (0.6) 0.65 (0.6)
Constipation 0.36 (0.7) 0.42 (0.6) 0.53 (0.7) 0.52 (0.7) 0.55 (0.5)
Spitzer 6.54 (1.8) 7.06 (1.7) 7.24 (2.2) 7.40 (1.9) 7.97 (1.4)
Data are expressed as mean (SD).
Current Medical Research & Opinion Volume 28, Number 11 November 2012
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opioid-naive patients with oral morphine14, transdermal
buprenorphine15, and transdermal fentanyl16. The reduced
tendency to increase the dose, already observed in animal
models5,6, may reflect a less toleragen effect of TP, possibly
due to its pharmacological characteristics with a dual anal-
gesic mechanism3.
TP seems to be particularly appropriate for patients with
neuropathic pain17,18. TP was equally effective, regardless
of the mechanisms assessed by clinical judgment, as well as
tools commonly used for assessing predominantly neuro-
pathic pain, such as PainDETECT. While there is good
evidence that screening tools may provide a common lan-
guage among researchers and a guidance for further diag-
nostic evaluation, they should not replace clinical
judgment19. However, the relatively low number of
patients participating in this preliminary trial does not
provide conclusive information, and trials with a larger
number of patients could identify subclasses of patients
who could benefit from TP.
TP was well-tolerated, as only 7% of patients discon-
tinued TP for alternative treatments or poor compliance
with TP therapy. This rate was considered acceptable,
given the reported need to switch to other opioids from
morphine because of unfavorable responses in the cancer
population20. The percentage of patients who discontin-
ued TP (7%) seems to be even less than patients treated
with oral morphine (13%), transdermal buprenorphine
(15%), and transdermal fentanyl (about 14%)
reported in previous studies with a similar design and
duration14–16. In studies of non-cancer pain, TP was asso-
ciated with a lower rate of discontinuation in comparison
with oxycodone7,8,10. The occurrence of expected opioid-
related adverse effects was low and these effects resolved
over time. Finally, the quality-of-life score was improved
after initiation of TP therapy.
The use of adjuvant drugs administered prior to enter-
ing the study or symptomatic drugs did not change during
the study period, confirming the efficacy and tolerability of
the drug, particularly regarding gastrointestinal adverse
effects which are frequently associated with opioid
therapy21.
This study was the first performed in cancer patients,
and the findings require confirmation in controlled studies
with a larger number of patients. Like most studies in
patients with cancer pain, it was limited by its open-
label, uncontrolled design, the number of patients lost in
follow-up, and discontinuation of the treatment for various
reasons. However, a low drop-out rate was found, suggest-
ing that TP may be of particular benefit to opioid-naive
patients or, for example, in the elderly. More data on dif-
ferent kinds of cancer population are needed, for example
patients with a lower performance status. Moreover, an
interesting issue to be explored is the question of the
dose, as the manufacturer recommends a maximum dose
of 400–500mg/day, which would be the dose range for
many cancer patients with pain. Data regarding the
effect on the inhibition of norepinephrine reuptake at
such high doses are unknown. As mentioned above, spe-
cific cancer population may benefit from TP treatment.
Finally, as it is frequently the case in clinical practice, a
change of opioid is required for a variety of reasons, and it
would be of interest to explore the conversion ratio exist-
ing between TP and other opioids, although it has been
suggested that an equianalgesic ratio with oral morphine
would be 1:2.522.
Conclusion
TP started in doses of 100mg/day was well-tolerated and
effective in opioid-naive patients with cancer pain and
could be considered as a flexible drug to be used for the
management of moderate–severe cancer pain. Four weeks
after starting TP, responsive patients were receiving a
mean dose of less than 200mg/day, suggesting a slow devel-
opment of tolerance.
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